← Hims Hers Health overview

Hims Hers Health vs Alignment Healthcare LLC: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Hims Hers Health Inc (HIMS)

Q3 2026
▲2▼2

Hims & Hers grew fast but faced FTC suit and rising losses

  • Strong revenue and subscriber growth Q2 revenue jumped 38% to $753.2 million and subscribers rose 18.5% to about 2.9 million, prompting management to raise full-year guidance to $3.1–3.3 billion. This top-line momentum showed the business is still expanding quickly.

    It explains the main positive force behind the stock during the quarter.

  • GLP-1 traction and international expansion Barclays raised its price target to $39, citing traction in GLP-1 weight-loss drugs, helped by the Novo Nordisk partnership and the Eucalyptus acquisition that expanded Hims into the UK, Australia, and Canada.

    It highlights analyst optimism and new growth avenues that supported the stock.

  • FTC lawsuit over data and billing The Federal Trade Commission sued Hims over health-data sharing and deceptive billing, causing the stock to drop about 14.7% and triggering multiple law-firm investigations. This legal risk weighed heavily on investor sentiment.

    It was the biggest negative event that moved the stock during the quarter.

  • Profitability deteriorated Hims reported a $0.37 per-share loss, gross margin fell to about 64%, free cash flow was negative $68 million, and an $81 million Eucalyptus charge hit results. Visa dispute-monitoring and weight-loss cost pressures added more uncertainty.

    It shows the financial counterweight that offset strong revenue growth.

August 2026
▼2▲1

Hims & Hers Q2 revenue beats but losses and legal risks weigh

  • Strong Q2 revenue growth and raised guidance Hims & Hers reported Q2 2026 revenue up 38% to $753.2 million, beating estimates, with subscribers rising 18.5% to about 2.9 million. Management raised full-year revenue guidance to $3.1–3.3 billion, signaling confidence in demand.

    This is the main positive fundamental driver for the period, showing the business is still growing quickly.

  • Profitability deteriorated sharply The company swung to a $0.37 per-share loss, gross margin fell to about 64% from 76%, operating expenses rose 48%, and free cash flow was negative $68 million. An $81 million Eucalyptus-related charge and weight-loss strategy shift drove the miss.

    This explains the sharp negative reaction in the stock despite strong revenue, as investors focused on losses and cash burn.

  • Escalating legal and billing risks Visa's dispute-monitoring program could bring a $75,000 penalty and a 1.5% dispute cap. The FTC and state legal actions are escalating, and a consumer class action adds to the legal overhang, threatening fines and reputational damage.

    These legal and payment risks are new developments that weigh on the stock and could hurt future growth.

  • Weight-loss market cost pressures and cheaper GLP-1 potential Cost pressures in the weight-loss market are a headwind, but cheaper GLP-1 pricing could boost demand. The balance between pricing pressure and volume growth remains uncertain, keeping the stock volatile.

    This captures the mixed impact of pricing trends on demand and margins, a key uncertainty for the period.

Latest
▼3▲1

Visa billing crackdown and FTC lawsuit hit HIMS; growth stays strong

  • Visa puts HIMS in dispute-monitoring program Visa placed Hims & Hers in its Acquirer Monitoring Program after a surge in credit-card disputes tied to weight-loss subscriptions, with a possible $75,000 penalty and a requirement to keep disputes below 1.5% for three months. This threatens billing reliability and could slow subscriber growth, pushing the stock down.

    This is the main new negative event this period and directly pressures HIMS's price.

  • FTC and state regulators escalate legal action The FTC and state regulators filed a civil enforcement action, and a consumer class action targets privacy and subscription practices. The CEO says the FTC misunderstands the company, but the legal fight adds costs and reputational risk that weigh on the stock.

    This is a new escalation of the legal pressure that is a core driver of HIMS's risk profile.

  • Q2 revenue jumps 38% and outlook raised Hims & Hers raised its 2026 revenue outlook to $3.1–$3.3 billion after Q2 sales rose 38.2% to $753.2 million, beating estimates. Subscribers grew 18.5% to about 2.9 million, showing demand is still strong and supporting the stock.

    This is the main new positive fundamental update this period and shows the growth story remains intact.

  • Margins shrink and cash burn deepens Gross margin fell to 63.8% from 76%, operating expenses rose 48.4%, and free cash flow was negative $68 million with an $86.3 million net loss. The company is spending heavily to grow, which pressures profits and keeps the stock volatile.

    This is the key counterweight to the revenue beat and explains why the stock still faces pressure.

▼2

HIMS Q2 loss and margin hit overshadow revenue beat

  • Q2 loss and margin collapse Hims & Hers reported a second-quarter loss of $0.37 per share, swinging from a $0.17 profit a year earlier. Gross margin fell to 64% from 76%, hit by an $81 million one-time cost tied to the Eucalyptus acquisition, a weight-loss strategy shift, and FTC legal reserves. This profit miss is what pushed the stock down.

    The earnings miss and margin drop are the main new financial event driving the stock lower this period.

  • Revenue beat and raised guidance Revenue rose 38% to $753.2 million, beating the roughly $699 million analysts expected, and the company raised its full-year revenue outlook to $3.1 billion to $3.3 billion. This shows demand is still strong, but investors focused on the loss and costs, so the stock still fell.

    It is the positive counterweight in the same earnings report and explains why the selloff was not larger.

  • CEO defends FTC lawsuit, touts cheaper GLP-1s CEO Andrew Dudum said the FTC lawsuit is more about publicity than a real resolution, and he expects cash-paying patients to eventually pay $40 to $50 a month for branded weight-loss drugs, down from $150 to $200. Cheaper pricing could boost demand, but the lawsuit still threatens fines and trust.

    It updates the biggest legal overhang and gives a concrete path to lower prices that could help future demand.

  • Weight-loss pill market cost pressure Hims & Hers and Novo Nordisk both fell even after strong growth, as investors worried about rising costs in the weight-loss pill market. Novo Nordisk's Wegovy pill sales missed expectations, adding to concerns that the branded GLP-1 push may be less profitable than hoped.

    It shows the cost and competition pressure in the core weight-loss business that is weighing on HIMS shares.

July 2026
▲2▼2

HIMS: FTC privacy lawsuit and law firm probes hit growth story

  • GLP-1 inflection and FDA peptide decision Barclays raised its price target to $39, citing a clear pickup in Hims & Hers' GLP-1 weight-loss business after the Novo Nordisk partnership, with website traffic up 35% and app users up 21%. A July FDA committee decision on peptides could open another growth avenue.

    This is the main positive force behind the stock and explains why it had been rising before the FTC news.

  • Novo Nordisk deal and Eucalyptus acquisition expand reach Hims & Hers is deepening its move into prescription weight management by offering Novo Nordisk's Wegovy and Ozempic, and its Eucalyptus acquisition adds scale in the UK, Australia, and Canada. This broadens revenue sources but raises questions about margins and regulatory exposure.

    It shows the concrete business expansion driving the growth narrative, a key reason investors were optimistic.

  • FTC lawsuit over data sharing and billing The FTC sued Hims & Hers, alleging it shared users' health data with advertisers like Meta and Snap and used deceptive billing and cancellation practices. The stock fell about 14.7% on the news, as the lawsuit threatens fines, reputational damage, and its core trust-based business model.

    This is the biggest new negative event and the main reason the stock dropped sharply this period.

  • Multiple law firm investigations into securities law violations Several law firms, including Holzer & Holzer, Frank R. Cruz, Kessler Topaz, and Lowey Dannenberg, are investigating whether Hims & Hers misled investors about the FTC allegations. These probes can lead to class-action lawsuits, adding legal costs and uncertainty that weigh on the stock.

    It shows the FTC issue is escalating into potential investor lawsuits, a fresh negative overhang.

▲2▼2

HIMS: FTC privacy lawsuit and law firm probes hit growth story

  • GLP-1 inflection and FDA peptide decision Barclays raised its price target to $39, citing a clear pickup in Hims & Hers' GLP-1 weight-loss business after the Novo Nordisk partnership, with website traffic up 35% and app users up 21%. A July FDA committee decision on peptides could open another growth avenue.

    This is the main positive force behind the stock and explains why it had been rising before the FTC news.

  • Novo Nordisk deal and Eucalyptus acquisition expand reach Hims & Hers is deepening its move into prescription weight management by offering Novo Nordisk's Wegovy and Ozempic, and its Eucalyptus acquisition adds scale in the UK, Australia, and Canada. This broadens revenue sources but raises questions about margins and regulatory exposure.

    It shows the concrete business expansion driving the growth narrative, a key reason investors were optimistic.

  • FTC lawsuit over data sharing and billing The FTC sued Hims & Hers, alleging it shared users' health data with advertisers like Meta and Snap and used deceptive billing and cancellation practices. The stock fell about 14.7% on the news, as the lawsuit threatens fines, reputational damage, and its core trust-based business model.

    This is the biggest new negative event and the main reason the stock dropped sharply this period.

  • Multiple law firm investigations into securities law violations Several law firms, including Holzer & Holzer, Frank R. Cruz, Kessler Topaz, and Lowey Dannenberg, are investigating whether Hims & Hers misled investors about the FTC allegations. These probes can lead to class-action lawsuits, adding legal costs and uncertainty that weigh on the stock.

    It shows the FTC issue is escalating into potential investor lawsuits, a fresh negative overhang.

Alignment Healthcare LLC (ALHC)

Q3 2026
▲2▼1

Whistleblower Lawsuit and Investigations Hit ALHC Despite Strong Results

  • Whistleblower lawsuit and securities investigations A former executive sued on July 8, claiming Alignment misclassified expenses to inflate profits and pay. The stock fell 16.7%, and multiple law firms launched investigations, raising legal costs and uncertainty.

    This is the main new negative event that drove the stock down in July.

  • Strong Q1 and Q2 revenue growth Alignment reported Q1 revenue up 33.3% to $1.24 billion and Q2 revenue up 31.6% to $1.34 billion, both beating estimates. Membership grew to 294,100, and the medical benefits ratio improved.

    These results show underlying business strength that supports the stock despite legal issues.

  • Higher 2026 Star Ratings Improved Star Ratings for 2026 could lead to higher future reimbursement from Medicare, boosting revenue and profitability. This is a positive fundamental development for the company.

    Star Ratings are a key driver of future Medicare payments and thus a positive catalyst.

July 2026
▲2▼1

Whistleblower Lawsuit and Investigations Hit ALHC Despite Strong Results

  • Whistleblower lawsuit and securities investigations A former executive sued on July 8, claiming Alignment misclassified expenses to inflate profits and pay. The stock fell 16.7%, and multiple law firms launched investigations, raising legal costs and uncertainty.

    This is the main new negative event that drove the stock down in July.

  • Strong Q1 and Q2 revenue growth Alignment reported Q1 revenue up 33.3% to $1.24 billion and Q2 revenue up 31.6% to $1.34 billion, both beating estimates. Membership grew to 294,100, and the medical benefits ratio improved.

    These results show underlying business strength that supports the stock despite legal issues.

  • Higher 2026 Star Ratings Improved Star Ratings for 2026 could lead to higher future reimbursement from Medicare, boosting revenue and profitability. This is a positive fundamental development for the company.

    Star Ratings are a key driver of future Medicare payments and thus a positive catalyst.

Latest
▲1▼1

Legal Cloud Grows as Strong Q2 Earnings Beat Estimates

  • More law firms join accounting investigation Kaplan Fox, Holzer & Holzer, Hagens Berman, Lowey Dannenberg, and Frank R. Cruz all launched or continued investigations into Alignment's accounting. This keeps the whistleblower scandal alive, raising legal costs and uncertainty that weigh on the stock.

    This is the main new negative force this period, extending the legal overhang from earlier reports.

  • Q2 revenue and profit beat expectations Alignment reported Q2 revenue of $1.34 billion, up 31.6%, and earnings per share of $0.17, both above analyst estimates. Membership grew to 294,100, and the medical benefits ratio improved, showing the core business is strong.

    This is the only new positive fundamental news this period, providing a counterweight to the legal issues.

▼2▲1

Whistleblower Accounting Claims Trigger Investigations, Stock Plunge

  • Strong Q1 Earnings and Membership Growth Alignment Healthcare reported Q1 revenue of $1.24 billion, up 33.3% year-over-year, with earnings per share beating expectations. Membership grew by 48,500 to 284,800, and analysts raised full-year earnings estimates. Higher Star Ratings across all plans for 2026 could boost future reimbursement. This positive news initially pushed the stock up 10.7%.

    This is a key positive driver that contrasts with the negative news later in the period, providing a balanced view.

  • Whistleblower Lawsuit Alleges Financial Manipulation On July 8, a former executive filed a whistleblower lawsuit alleging Alignment misclassified operating expenses as capital expenditures to inflate adjusted EBITDA and boost stock price and executive pay. The company denies the claims and vows to defend itself. The stock fell 16.7% on the news, its worst drop since February 2024.

    This is the primary negative event that caused a sharp stock decline and triggered multiple investigations.

  • Multiple Law Firms Launch Investigations Following the whistleblower lawsuit, law firms Block & Leviton, Hagens Berman, Kaplan Fox, and Bragar Eagel & Squire announced investigations into Alignment for potential securities law violations. These investigations could lead to lawsuits and further pressure the stock as legal costs and uncertainty rise.

    These investigations amplify the negative impact and keep the issue in the spotlight, affecting investor sentiment.

© 2026 MarketDXWhy